The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
Life Sciences Superpower
A second report from PwC for the Association of the British Pharmaceutical Industry reveals why the UK needs to build its position as a world-leading hub for medicines development and discovery.Read the Life Sciences Superpower report from PwC
Transforming lives, raising productivity
A new report from PwC for the Association of the British Pharmaceutical Industry reveals a picture of variable and slow access to the newest, innovative treatments.Read the report from PwC on the value of medicines
ABPI response to Clinical Research Implementation Plan publication
The governments of the four nations of the UK have published a second joint implementation plan for improving clinical research in the UK.
Latest Disclosure UK data: Highest ever rate of health professionals agreeing to be named
The latest information on ‘transfers of value’ made to healthcare organisations and health professionals in 2021 by pharmaceutical companies is published today on Disclosure UK.
Act now to bring £68bn economic boost to the UK through new research investment
The UK life science sector faces a “moment of truth” according to a new report produced by PwC for the ABPI.
ABPI welcomes Moderna investment
Moderna has signed an agreement with the UK Government to establish an mRNA Innovation and Technology Center in the UK.
Latest blogs and events
The Innovative Medicines Fund - Good news for patients but has an opportunity been missed to be more ambitious?
NHS England and Improvement (NHSE/I) has announced the launch of the Innovative Medicines Fund. The ABPI’s Director of Value and Access Policy, Paul Catchpole, provides further commentary on the announcement.
Working together, we are all determined to create more medicines for pregnant women
Steve Hoare, the ABPI's Head of Safety and Quality, talks about how industry is trying to address the lack of medicines approved for pregnant women.
Worth the wait – The Goldacre review
Our thoughts on Professor Ben Goldacre’s “Better, broader, safer” report into health data.
Innovative medicines can bring hope to people with rare diseases – let’s get them to patients
England’s Action Plan for Rare Diseases contains important commitments to ensure that people with rare diseases get faster diagnosis, better care and timelier access to the treatments they desperately need.
Key content hubs
We stand in solidarity with the people of Ukraine and condemn the invasion of their country. As an industry dedicated to saving lives, we stand for peace.
The COP26 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
Find out more about the potential of the UK’s life sciences sector if we deliver the government vision in full and at pace https://t.co/0biTNbQ6oS— ABPI (@ABPI_UK) July 1, 2022
What is the potential of unlocking the power of the UK’s #LifeSciences sector?— ABPI (@ABPI_UK) June 30, 2022
Our new report shows the economic and patient benefits to supporting our world-beating sector